Drugs / EIK1004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06907043 | Apr 2025 → Dec 2028 expected | cancer | Eikon Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-07-20 | Impact Therapeutics, Inc. | Results ESMO 2026 | 塞纳帕利及PARP1选择性抑制剂（IMP1734、IMP1707）的研究结果入选ESMO impacttherapeutics.com ↗
我们很高兴塞纳帕利及我们的两款新型选择性 PARP1 抑制剂 IMP1734 和 IMP1707 的最新临床数据已被接收在 2026 年 ESMO 年会上进行展示。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-20 | Impact Therapeutics, Inc. | ESMO 2026 | 塞纳帕利及PARP1选择性抑制剂（IMP1734、IMP1707）的研究结果入选ESMO impacttherapeutics.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EIK1004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06907043 ↗ |
| Known as | IMP1707 | “This study will evaluate the safety, tolerability and preliminary efficacy of EIK1004 (IMP1707) as monotherapy in patients with recurrent, advanced/metastatic solid tumors.” NCT06907043 ↗ |
| Action | Inhibit | “PARP1 selective inhibitor” NCT06907043 ↗ |
| Route | Oral | “oral tablet(s) daily” NCT06907043 ↗ |
| Target | PARP1 | “PARP1 selective inhibitor” NCT06907043 ↗ |